Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence

Joseph P. McEvoy

doi:10.4088/JCP.NU19047BR3C

Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence

Joseph P. McEvoy

Psychiatry and Health Behavior

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Tardive dyskinesia (TD) is a condition of potentially irreversible abnormal involuntary movements associated with dopamine receptor blocking agents, such as antipsychotics. While prevention is the best strategy, it is not always possible. This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).

Original language	English (US)
Journal	The Journal of clinical psychiatry
Volume	81
Issue number	6
DOIs	https://doi.org/10.4088/JCP.NU19047BR3C
State	Published - Sep 29 2020

ASJC Scopus subject areas

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4088/JCP.NU19047BR3C

Cite this

@article{5bcf126b1b0240f7b6de7b3616417d9e,

title = "Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence",

abstract = " Tardive dyskinesia (TD) is a condition of potentially irreversible abnormal involuntary movements associated with dopamine receptor blocking agents, such as antipsychotics. While prevention is the best strategy, it is not always possible. This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).",

author = "McEvoy, {Joseph P.}",

year = "2020",

month = sep,

day = "29",

doi = "10.4088/JCP.NU19047BR3C",

language = "English (US)",

volume = "81",

journal = "The Journal of clinical psychiatry",

issn = "0160-6689",

publisher = "Physicians Postgraduate Press Inc.",

number = "6",

}

TY - JOUR

T1 - Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence

AU - McEvoy, Joseph P.

PY - 2020/9/29

Y1 - 2020/9/29

N2 - Tardive dyskinesia (TD) is a condition of potentially irreversible abnormal involuntary movements associated with dopamine receptor blocking agents, such as antipsychotics. While prevention is the best strategy, it is not always possible. This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).

AB - Tardive dyskinesia (TD) is a condition of potentially irreversible abnormal involuntary movements associated with dopamine receptor blocking agents, such as antipsychotics. While prevention is the best strategy, it is not always possible. This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).

UR - http://www.scopus.com/inward/record.url?scp=85092498903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092498903&partnerID=8YFLogxK

U2 - 10.4088/JCP.NU19047BR3C

DO - 10.4088/JCP.NU19047BR3C

M3 - Article

C2 - 32991793

AN - SCOPUS:85092498903

SN - 0160-6689

VL - 81

JO - The Journal of clinical psychiatry

JF - The Journal of clinical psychiatry

IS - 6

ER -

Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this